Balance Sheet
Cash Flow Statement
AmortizationAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Dr Reddys Laboratories (RDY) over the last 14 years, with Q4 2025 value amounting to $3.0 million.

  • Dr Reddys Laboratories' Asset Writedowns and Impairment rose 652340.74% to $3.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $19.9 million, marking a year-over-year increase of 12166.19%. This contributed to the annual value of $20.0 million for FY2025, which is 190000.0% up from last year.
  • As of Q4 2025, Dr Reddys Laboratories' Asset Writedowns and Impairment stood at $3.0 million, which was up 652340.74% from -$11.2 million recorded in Q3 2025.
  • Over the past 5 years, Dr Reddys Laboratories' Asset Writedowns and Impairment peaked at $106.9 million during Q1 2021, and registered a low of -$11.2 million during Q3 2025.
  • For the 5-year period, Dr Reddys Laboratories' Asset Writedowns and Impairment averaged around $14.9 million, with its median value being $1.3 million (2023).
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first soared by 3326661217.41% in 2023, then tumbled by 20109.19% in 2025.
  • Quarter analysis of 5 years shows Dr Reddys Laboratories' Asset Writedowns and Impairment stood at $95.0 million in 2021, then crashed by 92.63% to $7.0 million in 2022, then tumbled by 81.13% to $1.3 million in 2023, then tumbled by 103.59% to -$47374.8 in 2024, then soared by 6523.41% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q4 2025, -$11.2 million for Q3 2025, and $19.1 million during Q2 2025.